# A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

> **NCT03823339** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 300 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin degludec/liraglutide

## Key facts

- **NCT ID:** NCT03823339
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-29
- **Primary completion:** 2020-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03823339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03823339, "A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03823339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*